Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

First-in-class immune-stimulating antibody conjugate BDC-4182 in Phase 1 dose escalation study, initial clinical data expected in 3Q 2026 Cash ...

Multi-Organization Partnership Announces $2.5 Million for Aging & Cancer Research

Taking aim at the leading risk factor for cancer, The Mark Foundation for Cancer Research and the Samuel Waxman Cancer Research Foundation (SWCRF) today announced $2.5 million to support science at ...

Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides runway into the second half of 2028, through expected clinical proof-of-concept readout for KOMODO-1 ...

Voyager Acquisition Corp.: Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG

Voyager Acquisition Corporation (NASDAQ: "VACHU," "VACH," "VACHW") ("Voyager" or the "Company") today announced that holders of 25,217,315 of the Company's ...